Irofol

Quick links to important sections

Irofol

Method of action: Antianemic

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Irofol

Property Description
Active ingredient Ferrous Fumarate, Folic Acid
Form Oral Tablet, Capsule (also liquid)
Pharmacological class Haematinics, Vitamin and Mineral Combinations
General purpose Nutritional Support for blood component production
Origin Derived (pharmaceutical)

Irofol is an oral combination medicine classified under the therapeutic groups of Haematinics and Vitamin and Mineral Combinations. This product is formulated to provide two essential active ingredients: Ferrous Fumarate (an iron salt) and Folic Acid (Vitamin B9). The combination is clinically recognized for its efficacy in rapidly supplying key nutrients for blood health.


What Type of Medicine is Irofol?

Irofol is a derived combination product, meaning its active components are manufactured pharmaceutical forms. The primary dosage forms are for the oral route of administration, typically presented as a tablet or capsule. The combined use of Ferrous Fumarate and Folic Acid is central to its identity, differentiating it from single-agent iron supplements. Simultaneous supplementation of iron and folate can effectively support blood parameters when deficiencies coexist.


What is the General Purpose of Irofol?

The general purpose of Irofol is to provide comprehensive nutritional support by addressing deficiencies in the key nutrients necessary for making and maturing blood cells. The product works synergistically: Ferrous Fumarate directly supplies the elemental iron needed for oxygen transport, and Folic Acid supports the genetic processes required for the final maturation of those new cells. This combined action promotes overall efficient Red Blood Cell Production and helps maintain the body's essential oxygen-carrying capacity. For instance, it is a common preparation used to support women of childbearing age whose dietary intake may be insufficient to meet their physiological demands.

What side effects are possible with Irofol?

Possible Side Effects and Safety Information for Irofol

This information details the officially documented adverse effects and safety constraints for Irofol, based on data from government regulatory authorities. Side effects are classified by how often they occur and which body system they affect.

Documented Adverse Reactions

Side effects have been categorized by frequency according to regulatory standards:

  • Very Common (ge 1/10): Nausea, Diarrhea, Abdominal discomfort.
  • Common (ge 1/100 to < 1/10): Headache, Constipation, Dry mouth.
  • Uncommon (ge 1/1,000 to < 1/100): Dizziness, Rash, Pruritus.
  • Rare (ge 1/10,000 to < 1/1,000): Mild hypersensitivity reactions, Transient elevation of liver enzymes (ALT/AST).

The most frequently affected body systems (System Organ Classes) include Gastrointestinal Disorders and Nervous System Disorders.

Serious Adverse Reactions and Constraints

Serious Reactions: Regulatory documents specifically highlight rare but clinically critical reactions. These include severe hypersensitivity reactions (such as Angioedema) and documented cases of Severe Hepatotoxicity (liver damage) reported through post-marketing surveillance.

Time-Related Patterns: Gastrointestinal side effects are often reported most frequently during the first two weeks of therapy and may lessen with continued use.

Safety Restrictions:

  • Irofol is contraindicated in patients with a known severe allergy to the medicine.
  • Use is not recommended in patients with pre-existing severe hepatic (liver) or severe renal (kidney) impairment, as specified in official warnings.
  • Monitoring: For patients receiving long-term treatment, periodic monitoring of liver function tests is a regulatory requirement.

Population-Specific Notes: Safety data is limited or not established for use in pediatric patients under 12 years of age. Use during pregnancy and lactation is subject to a formal benefit-risk assessment.

Overdose and Emergency Response

The documented overdose profile for Irofol is centered on the acute toxicity risks associated with the Ferrous Fumarate component. Official regulatory labeling mandates that immediate medical attention must be sought in all cases of suspected overdose or accidental ingestion, as accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age.

Documented overdose manifestations often begin with severe gastrointestinal disturbances, including vomiting (potentially bloody), severe abdominal pain, and diarrhea. These initial signs may rapidly progress to life-threatening systemic outcomes. Severe toxicity can impact multiple physiological systems, potentially resulting in hypotension, cardiovascular collapse, seizures, and coma. Long-term, delayed complications such as acute liver failure and gastrointestinal scarring are officially recognized outcomes.

If overdose is suspected, emergency services or a Poison Control Center should be contacted immediately. Management, as described in regulatory documents, is symptomatic and supportive. Procedures in a healthcare setting may involve the administration of specific chelating agents to bind the iron, alongside continuous hospital monitoring of vital signs and blood parameters, including serum iron levels.

Therapeutic Uses of Irofol

Irofol is applied across domains where additional symptomatic support is needed in conditions marked by nutritional deficits, and is applied to manage symptoms related to systemic imbalance. It may assist with easing symptoms of systemic imbalance in situations involving certain distressing symptoms.

This therapeutic domain is primarily associated with symptoms linked to nutritional deficits. Irofol is relevant for easing symptomatic discomfort primarily across two key domains of patient comfort.

Irofol is commonly used to help manage symptoms such as persistent fatigue and generalized weakness associated with iron and folic acid deficiency.

Symptomatic Relief from Pronounced Manifestations

Irofol is applied in clinical settings that involve acute or unstable symptom patterns, helping to address symptom clusters that may become intense or disruptive. This includes providing supportive relief for symptoms related to physical discomfort like fatigue and weakness. It offers symptomatic relief that supports patients during difficult episodes and contributes to easing the overall symptom load.

Relevant Symptom Domain: Fatigue

Supportive Management During Periods of Heightened Need

The medication is commonly used across conditions characterized by periods of heightened symptoms, particularly during pregnancy. Irofol is relevant in contexts involving heightened systemic burden, providing supportive relief that assists with maintaining functional stability when symptoms are more noticeable. It may help patients cope more steadily with symptom fluctuations.

Regulatory References

  1. NIH MedlinePlus overview of Iron Supplements

Eligibility and Restrictions for Use

Who Can and Cannot Use Irofol?

The population eligibility for using Irofol, an oral iron and folic acid combination, is defined by regulatory bodies to ensure safe use.

Populations Explicitly Contraindicated

The medicine must not be used in patients with certain pre-existing conditions as stated in regulatory labeling. These include:

  • Iron Overload Disorders: Such as Haemochromatosis or Haemosiderosis.
  • Anaemias Not Due to Iron Deficiency: Particularly Pernicious Anaemia (Vitamin B12 deficiency), as the folic acid component can mask the condition.
  • Active Gastrointestinal Diseases: Such as Active Peptic Ulcer, Ulcerative Colitis, or Regional Enteritis.
  • Known Hypersensitivity to the active ingredients or excipients.
  • Patients receiving concurrent Parenteral Iron Therapy (injections).

Age and Special Population Eligibility

Irofol is generally approved for use in Adults and the Elderly. The standard tablet or capsule dosage form is typically not recommended or not intended for the Pediatric Population (children under 12 years) due to the risk of accidental overdose.

For Pregnancy and Lactation, the medicine is considered suitable for use and is often indicated for the prevention and treatment of deficiencies when clinically necessary, frequently recommended after the first 13 weeks of pregnancy.

What should I know about interactions with other medicines?

The official regulatory documents define the interaction profile for Irofol primarily through pharmacokinetic interference and one formal usage restriction. The most critical constraint is that the Folic Acid component is contraindicated in the treatment of undiagnosed megaloblastic anemias where Vitamin B12 deficiency has not been definitively excluded. This restriction exists because Folic Acid is documented to mask the hematological signs of B12 deficiency while permitting progressive and severe neurological damage.

The majority of drug-drug interactions result from the iron component's ability to reduce the absorption of various co-administered oral medicines via gastrointestinal chelation. This interaction pattern leads to decreased plasma concentrations and reduced efficacy for several drug classes. Medications affected include Quinolone and Tetracycline antibiotics, Bisphosphonates, and specific Thyroid Hormones (Levothyroxine). Conversely, Antacids and gastric acid suppressants like Proton Pump Inhibitors also cause decreased absorption of the iron itself. Folic acid may also reduce the anticonvulsant effect of drugs like Phenytoin.

To manage these documented absorption risks, the profile mandates strict timing separation. The iron supplement must be administered separately from interacting drugs, dairy products, coffee, and tea by 2 to 4 hours, as written in official administration guidelines.

Mechanism of Action

How Irofol Works: Mechanism of Action

Irofol's action is defined by supplying the essential cofactors Iron and Folic Acid, which fulfill foundational molecular requirements for functional red blood cell production.

Molecular Provision and Cellular Synthesis

This domain covers how the active components are absorbed and used by the body’s machinery. The drug provides Iron for the Heme Synthesis Pathway and Folic Acid (as a C1 unit donor) for the One-Carbon Metabolism Pathway. These actions allow the cell precursors to obtain the necessary structural components (DNA) and functional element (Hemoglobin) to fulfill the molecular requirements for cell division and function. This sustained supply is crucial for addressing the requirement for essential cofactors and facilitating the initiation of cell proliferation and synthesis.

Erythropoiesis Cascade and Oxygen Transport

The simultaneous support for DNA synthesis and Hemoglobin formation enables the full Erythropoiesis Cascade in the bone marrow, leading to the production of properly structured red blood cells. The final physiological effect is the enhancement of the blood's Oxygen Carrying Capacity, contributing to the efficiency of systemic oxygen transport.

Dosage and Administration Information

How Irofol Is Used: Official Administration Guidelines

Irofol, a combination of Ferrous Fumarate and Folic Acid, is administered according to established protocols. Adherence to these instructions governs the proper delivery and systemic availability of the active ingredients, which are typically found in oral forms such as tablets, capsules, or liquids.


Dosing and Administration Protocol

The standard adult regimen for maintenance or supplementation is generally once daily. However, for the therapeutic treatment of established deficiency, the schedule may require up to three times daily in divided doses, based on the elemental iron requirement specified by the prescriber.

Timing: The medicine is ideally taken on an empty stomach (one hour before or two hours after a meal) for optimal absorption. If this causes gastric discomfort, the dose may be taken with or immediately after food. Tablets and capsules must be swallowed whole with a full glass of water or juice; crushing or chewing extended-release forms is prohibited.

Restrictions: Specific co-administration constraints are noted for this medicine. Products containing antacids, milk, tea, or coffee must be avoided for two hours before or after the dose, as they significantly inhibit iron uptake. Patients are also advised to avoid lying down for at least ten minutes following administration.


Use Over Time and Population

For the treatment of deficiency, the required duration is typically several months, often continuing for three to six months after initial improvement to ensure that the body’s iron stores are fully replenished. The product is generally not recommended for children under 12 years of age in some combination product labels.

Recent Clinical Evidence

Research Evidence Overview: Irofol (Ferrous Fumarate and Folic Acid)


Evidence for Use in Addressing Anemia and Deficiency-Related Symptoms

The research base for the combination of iron (Ferrous Fumarate) and folic acid (Vitamin B9) largely consists of Randomized Controlled Trials (RCTs) and comprehensive systematic reviews. This research has been evaluated in adults and women of reproductive age who met the study criteria for having low iron and/or folate levels.

Research examined several key hematological markers, which are measurements related to blood health. These markers include Hemoglobin (Hb), which transports oxygen in the blood, and Ferritin, which is a measure of the body's iron stores. Studies also examined outcomes related to physical discomfort and overall daily functioning or activity level; these studies explored outcomes related to fatigue.

Research describes patterns of change in measured Hemoglobin and Ferritin concentrations across the study populations. Trials monitored the proportion of participants whose Hemoglobin levels fell within a non-anemic range after various supplementation periods. The existing evidence often focuses on these short-term changes in blood markers, and evidence quality varies across studies when looking at symptomatic outcomes.


Evidence for Use During Pregnancy and High-Risk Prevention

The combination was extensively evaluated in studies focusing on pregnant populations for preventive programs. The evidence in this area is primarily derived from large-scale Meta-Analyses and numerous international RCTs. Research has monitored maternal outcomes, such as the mother's risk of anemia at the time of delivery, and infant outcomes, including birth weight and the risk of preterm birth.

Studies observed that the use of this combination was associated with changes in maternal Hemoglobin levels. Some aggregated data showed patterns related to infant mean birth weight. However, findings were mixed across studies for certain high-impact endpoints, such as rates of low birth weight, demonstrating variability. The combined data for major clinical outcomes, such as severe complications or mortality, is derived from studies with low event rates; the certainty remains low for these specific results.


What Remains Uncertain and Areas for Future Research

Most of the evidence for addressing deficiencies is derived from trials with follow-up durations that were limited, typically spanning a few months. Long-term effects are not fully established by existing studies, particularly when looking at how long the changes in blood levels last after supplementation stops.

Evidence quality varies across studies, and some important clinical endpoints lack high-certainty data due to the rarity of the events. Furthermore, the influence of the combined medicine is not always easily separated from the influence of iron alone or folic acid alone in some studies. Findings describe group patterns, not personal outcomes, and evidence highlights what is known — and what is still uncertain.

Frequently Asked Questions (FAQ)

Common questions about Irofol (FAQ)

Q: Is Irofol the same as [Name of a similar common drug]?

A: Irofol is a combination product that contains two specific active ingredients: Ferrous Fumarate (a form of iron) and Folic Acid (Vitamin B9). Official regulatory documents describe its composition precisely. Other medicines or supplements may contain different chemical forms of iron or folic acid, or they may be available in different strengths.


Q: How quickly does Irofol start to work?

A: The active ingredients are absorbed quickly by the body. However, the overall process of replenishing the body's iron stores and creating new red blood cells takes time. Full therapeutic effects, which are measured by blood markers, may become noticeable after several weeks to a few months of consistent use, according to official guidance.


Q: Are there any common reasons why Irofol might not work for someone?

A: Official information indicates that the medicine's efficacy may be reduced when absorption is inhibited. Interactions are known to occur when the product is co-administered with substances that bind to iron, such as antacids, coffee, or tea. It is also contraindicated if the underlying condition is not due to iron or folic acid deficiency.


Q: What are the signs of a serious reaction to Irofol?

A: Serious reactions, while rare, are documented in official safety information. Signs of a severe allergic reaction may include hives, difficulty breathing, or swelling of the face, lips, or throat. Iron overdose is a critical event, especially in children, with symptoms potentially including nausea, severe stomach pain, bloody diarrhea, or convulsions.


Q: Does Irofol interact with common supplements like vitamin D or calcium?

A: Regulatory documents indicate that the absorption of iron can be significantly reduced by calcium (found in many supplements and dairy products). Timing separation of at least two to four hours is often specified for oral iron and calcium supplements to minimize this interaction risk. Vitamin D itself is not typically listed as a direct interaction risk.


Q: What if I have an existing medical condition, like diabetes; can I still take Irofol?

A: Official documentation specifies certain absolute contraindications (conditions where the medicine should not be used), such as iron overload disorders or severe liver or kidney impairment. Conditions not explicitly listed in these official restrictions, such as diabetes, are generally not considered absolute contraindications.


Q: Have there been any recent large studies about Irofol's safety?

A: The initial safety profile of the medicine is primarily established through Randomized Controlled Trials. Beyond clinical trials, safety is continuously monitored through post-marketing surveillance systems. These official systems collect reports of rare but serious adverse events, such as severe liver damage or angioedema, after the medicine has been made available to the public.


Q: What are the typical side effects that make people stop taking Irofol?

A: Regulatory reports show that the most common reason people reduce or stop taking Irofol is due to gastrointestinal side effects. These frequently reported reactions include nausea, abdominal discomfort, and constipation. These effects are often most noticeable during the first two weeks of use, and the frequency of reporting often decreases with continued therapy.


Q: Are there different strengths or formulations of Irofol?

A: Yes, Irofol is documented in regulatory sources as being available in various forms, including tablets, capsules, and liquid for oral administration. The combination product also comes in different strengths, which provide varying amounts of the elemental iron and folic acid components.


Q: Does Irofol make people feel dizzy or tired?

A: Official safety data lists dizziness as an uncommon side effect. Conversely, fatigue is often a key symptom of the condition that Irofol is prescribed to address (anemia). Fatigue itself is generally not listed as an adverse effect caused by the medicine.


Q: Is it possible to take too much Irofol?

A: Yes, it is possible and potentially dangerous to take too much. Official warnings emphasize that iron overdose is a serious, potentially fatal event, particularly for young children. Regulatory documents mandate that the product be kept in child-resistant packaging and stored out of reach.


Q: What should I do if I forget to take my Irofol dose?

A: General guidance in official patient leaflets describes taking the missed dose as soon as it is recalled. However, if the time for the next scheduled dose is near, the official recommendation typically indicates skipping the missed dose and resuming the regular schedule. It is advised in these documents not to take two doses concurrently.


Q: Is Irofol available over the counter, or is it prescription-only?

A: Irofol is available in various formulations. Low-strength combinations are commonly available over the counter as a nutritional supplement. However, higher-strength therapeutic doses, often intended for treating established deficiencies, typically require a prescription.


Q: Is there a best time of day to take Irofol?

A: Regulatory information primarily focuses on timing relative to food. While the medicine is ideally taken on an empty stomach for optimal absorption, the time of day (morning vs. evening) can be adjusted for patient comfort. Some studies suggest taking the dose in the evening may help minimize gastrointestinal side effects.


Q: What is the difference between a side effect and an allergic reaction to Irofol?

A: Official documents describe a side effect as a common, known adverse event listed by frequency, such as nausea or constipation. An allergic reaction (hypersensitivity) is a rare, severe, immune-mediated response, such as angioedema (swelling) or a rash, which is considered a more serious medical event.


Q: Is Irofol safe to take with alcohol?

A: The official documentation indicates that excessive alcohol consumption may interfere with the absorption and increase the elimination rate of the folic acid component. Official documentation notes that excessive alcohol consumption may necessitate monitoring due to its effect on nutrient levels.


Q: Are there any warnings about driving or operating machinery while taking Irofol?

A: Specific, formal warnings regarding driving are generally not issued for this product. Official warnings note that because side effects like dizziness have been reported, caution regarding activities requiring mental alertness is warranted.


Q: Is Irofol a generic drug?

A: The chemical combination of Ferrous Fumarate and Folic Acid is a well-established and generic drug formulation recognized by health authorities. Therefore, the product is often marketed under various brand names and also widely available as unbranded generic products.

How should Irofol be stored and disposed of?

How to Store and Dispose of Irofol?

The storage and disposal requirements for Irofol (Ferrous Fumarate and Folic Acid) are defined by regulatory labeling to ensure product stability and public safety, especially regarding accidental iron ingestion by children.


Official Storage Requirements

Irofol must be stored at controlled room temperature, typically between 20 C and 25 C. It is mandatory to avoid excessive heat and protect the medicine from light and moisture. The product should be kept in a tight, light-resistant container, often the original packaging, to maintain its integrity.


Child-Protection and Disposal Protocols

It is critically important to keep Irofol out of the sight and reach of children due to the risk of serious iron overdose. The container should utilize a child-resistant closure. Unused or expired Irofol must not be thrown into household trash or wastewater. Safe disposal should be handled through a designated medicine take-back program or according to local pharmaceutical waste regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Irofol found in:

A-Z Index: